% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • korthh Nov 26, 2013 6:42 PM Flag

    Piper Jaffray Price Increase to $34.00 dollars

    Just seen it on their site. Can anyone tell me if this means some good news is about to be announced? What do you think?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • here is is: • Piper starts Insmed (INSM) at Overweight. Price target is $34. So it looks iniitial to me

      Sentiment: Hold

    • Dr. Schimmer is the analyst making the $34 12-month target. Apparently, he thinks the upcoming Phase 2 NTM results will be positive and the PPS will soar. I don't think this means good news is about to be announced, but who knows? If significant good news is announced within the next 30 days, I doubt it will be about the Phase 2 trial.

      Joshua Schimmer, MD

      Sr Research Analyst
      Joshua Schimmer, MD

      Josh Schimmer is a managing director and senior research analyst who joined Piper Jaffray in 2013 to cover biotechnology companies. Schimmer has been on the Street for more than 10 years; prior to joining Piper Jaffray, he worked in equity research at Lazard Capital Markets, Leerink Swann and Cowen and Company. In addition, he spent time on the buy side at Davidson Kempner as part of the healthcare investing team. Schimmer holds a Doctor of Medicine (MD) from the University of Toronto, where he specialized in Internal Medicine and sub-specialized in Rheumatology. He also holds an MBA from Harvard Business School.

      • 2 Replies to tycint
      • Wasn't it Dr. Joshua Schimmer who made the Piper Jaffray target? I believe he used to be with Lazard and was probably with them when they made their call at $28 If this is the same person, he has become more optimistic with regards to Insmed's short term potential. Can anyone confirm?


        Piper Jaffray Expands Biotechnology Research Platform with Addition of Josh Schimmer, MD

        11/7/2013 9:53:35 AM

        MINNEAPOLIS--(BUSINESS WIRE)--Nov. 7, 2013-- Piper Jaffray (NYSE: PJC) is pleased to announce the hiring of Josh Schimmer, MD as a managing director and senior research analyst based in the firm’s New York office. Schimmer will be focused on small- and mid-cap biotechnology companies with specific emphasis in core therapeutic areas, commercialization and strategic partnerships.

        Schimmer brings more than 10 years of experience to Piper Jaffray. He joined the firm from Lazard Capital Markets, and was previously at Cowen & Co., Leerink Swann, Deutsche Banc and Davidson Kempner. Schimmer holds a doctorate of medicine from the University of Toronto and a Master of Business Administration degree from Harvard Business School.

        "Piper Jaffray has a strong team of healthcare professionals and we are excited to be adding another research specialist in biotechnology with Josh's hire," commented Steph Wissink, co-director of equity research for Piper Jaffray. "With increased emphasis on core growth areas of biotech, we see opportunities to serve the needs of our clients and build upon our market-leading healthcare platform."

      • $34 12-month target is way to conservative...!

        Sentiment: Strong Buy

    • search shows that Piper Jaffray "initiated" coverage. Where do you see that they "increased" price target?


14.040.00(0.00%)Oct 21 4:00 PMEDT